Table 1.

Antitumor effects of interleukin 12 potentiated by various therapeutic modalities in experimental models

Therapeutic modality	Animals	Tumor cells	Refs.
Cyclophosphamide	Mice	MB-49 bladder carcinoma, B16 melanoma	[60]
Paclitaxel	Mice	MmB16 melanoma	[61]
5-fluorouracil	Mice	L1210 leukemia	[62]
5-aza-2′-deoxycitidine	Mice	L1210 leukemia, B16F10 melanoma	[58]
Mitomycin	Rabbits	Hepatocellular carcinoma	[63]
Mitoxantrone	Mice	L1210	[64]
Doxorubicin	Mice	L1210	[65]
Cisplatin	Mice	MmB16	[46]
IL-2	Mice	Mammary carcinoma	[66]
IL-18	Mice	MCA205 fibrosarcoma	[67]
TNF-α	Mice	B16F10 melanoma, Lewis lung carcinoma, L1 sarcoma	[45]
G-CSF	Mice	MmB16 melanoma	[53]
GM-CSF	Mice	MmB16 melanoma	[52]
IFN-α	Mice	B16F10 melanoma	[68, 69]
Cetuximab	Athymic mice	Human head and neck carcinoma	[30]
Vasostatin	Nude mice	CA-46 Burkitt lymphoma, SW620 human colon carcinoma	[70]
Radiotherapy	Mice	Lewis lung carcinoma	[71]
Cytokine-induced killer cells	Mice	DB7 mammary carcinoma	[72]
Vaccine (dendritic cells pulsed with tumor cell lysate)	Mice	B78-H1 melanoma Hepatocellular carcinoma BNL	[73] [74]
Vaccine (IL-2-transduced tumor cells)	Mice	TSA mammary adenocarcinoma SR-B10A glioma	[75] [76]
Peptide vaccine	Mice	Meth A sarcoma	[77]